MedImmune Expands University System of Maryland Research Collaboration
Monday, April 28, 2014
- Five Joint Research Projects Underway -
Gaithersburg, MD and Adelphi, MD, April 29, 2014 -- MedImmune, the global biologics research and development arm of AstraZeneca, and the University System of Maryland announced today that the initial research collaboration between MedImmune and the University of Maryland, Baltimore (UMB) has been expanded to include the University of Maryland, College Park and the University of Maryland, Baltimore County. The collaborators have also announced that they have identified the first five research projects to be undertaken under the expanded agreement. This follows the September 2013 announcement in which MedImmune and UMB announced a five-year, $6 million collaboration to drive novel bioscience research in the state of Maryland (view press release).
- Oncology: evaluate a molecule that simultaneously inhibits suppression of anti-tumor immunity and boosts activation of tumor-reactive T cells.
- Respiratory, Inflammation and Autoimmunity: evaluate the role of specific phagocytes in inflammatory diseases.
- Cardiovascular and Metabolic Disease: explore the mechanism and role of stem cells in cardiac regeneration.
- Infectious Diseases: explore the immune system-stimulating properties of key innate immune system proteins for use in novel vaccines.
- Infectious Diseases: study a novel nanoparticle vaccine delivery system with unique stability and immune-stimulating potential.